Our Resources

As the FDA and HHS initiate a strategic review of the infant formula industry through Operation StorkSpeed, ObvioHealth’s experience in modernizing infant nutrition research offers a timely and relevant model for faster, safer, and more scalable clinical trials.

In response to rising healthcare demands, ObvioHealth is redefining clinical trials through decentralized models and patient-first technology that improves access, engagement, and data quality.

AI-Driven Enhancements in ObvioGo 2.2 Redefine Efficiency, Compliance, and Innovation in Clinical Trial Management

Ready. Set. Food! and ObvioHealth successfully recruited 1,100 diverse participants for the EASE trial two months ahead of schedule, leveraging the ObvioGo® platform and digital strategies to advance research on early allergen introduction and improve infant health outcomes.

ObvioHealth welcomes sales veteran Richard Watkins as CRO to guide the company’s shift to enterprise software. His proven leadership in SaaS and healthcare will help expand ObvioGo® 2.0’s impact on clinical trials worldwide.

ObvioHealth announces the appointment of seasoned healthcare executive Nicholas Campbell to its Board of Directors. Campbell brings expertise to accelerate digital innovation and advance clinical trial solutions.

VaxArt needed solutions for evaluating the safety and immunogenicity of its orally administered norovirus vaccine. Of particular importance was incorporating a way to quickly detect severe reactogenicity symptoms during the first week following vaccine administration. ​

The upgraded platform gives sponsors the ability to mix hybrid and virtual trial designs within one study, easily tailoring workflows to sites, locations, and study populations.